Russell Szmulewitz, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the optimal use of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer.

The optimal use of this agent is unclear, Szmulewitz explains. Though prior data show that patients with mCRPC have a benefit, he says that these patients already have comorbidities. It may be useful to use it in earlier settings in patients with high-volume bone metastases.

Currently in clinical practice, many physicians are using the agent prior to chemotherapy and in patients with bone-metastatic disease. Future studies will likely help demonstrate radium-223's benefit in earier settings, Szmulewitz adds. 

Russell Szmulewitz, MD

Articles

Dr. Szmulewitz on Optimal Use of Radium-223 in mCRPC